EUVIMEDEUVIMED entdecken
Open Access

Locally Ablative Therapies in Oligometastatic Breast Cancer

Tori C Nierenberg, Samantha M Thomas, Ian Halliday, Astrid Botty van den Bruele, Ton Wang, Laura H Rosenberger, Meghan R Flanagan, Gayle A DiLalla, E Shelley Hwang, Jennifer K Plichta

JAMA Surgery · 2026

DOI: 10.1001/jamasurg.2026.0098 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Surgery, 2026. Verfasst von Tori C Nierenberg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Duke University Medical Center, Durham, North Carolina. Hauptthemen laut MEDLINE: Breast Neoplasms, Bone Neoplasms, Ablation Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Management of de novo metastatic breast cancer (dnMBC) often focuses on palliation. As such, the potential survival benefit of surgery or ablative therapy remains unclear, particularly for those with oligometastatic disease.

Objective

To evaluate the association of surgical and/or locally ablative treatment of the primary and/or metastatic sites with overall survival (OS) in patients with single-site oligometastatic dnMBC. Design, Setting, and Participants This was a retrospective cohort study using the National Cancer Database. Patients diagnosed with oligometastatic, single-site (ie, brain, bone, liver, or lung) dnMBC receiving systemic therapy were selected from the National Cancer Database (2010-2020). Study groups included no locally ablative therapy/surgery (NLT), primary breast tumor resection only (BR), metastatic site ablative therapy only (MT), and both therapies (BR+MT). Logistic regression identified factors associated with treatment strategy. Multivariable modeling was used to estimate the association of treatment with OS. Data were analyzed from August 2024 to September 2025. Exposures NLT, BR, MT, or BR+MT therapies for oligometastatic, single-site dnMBC. Main Outcomes and Measures The primary outcome measure was OS.

Results

Among 22 433 patients (median [IQR] age, 61 [50-70] years; 22 126 female biological sex at birth [98.6%]; median [IQR] follow-up, 61.5 [60.7-62.5] months), bone-only metastases were most common in 15 441 (68.8%). Locally ablative therapies were uncommon (BR+MT, 1438 [6.4%]; MT, 2381 [10.6%]; BR, 3435 [15.3%] vs NLT, 15 179 [67.7%]). Older age (>70 years, odds ratio [OR], 2.49; 95% CI, 2.24-2.76 vs <50 years [reference]) and higher comorbidity score (>2, OR, 1.36; 95% CI, 1.16-1.60 vs 0 [reference]) were associated with NLT. Compared with NLT, BR (hazard ratio [HR], 0.62; 95% CI, 0.58-0.67) and BR+MT (HR, 0.60; 95% CI, 0.54-0.67) were associated with improved survival, but OS was worse for MT (HR, 1.22; 95% CI, 1.14-1.31). Conclusions and Relevance Results of this cohort study suggest that few patients with single-site dnMBC undergo surgical/ablative therapy, although BR+MT and BR only were associated with improved OS. However, if invasive interventions are considered for patients with single-site dnMBC, resection of the breast primary may be beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBone NeoplasmsAblation TechniquesHumansFemaleRetrospective StudiesMiddle AgedAgedSurvival RateLung NeoplasmsBrain NeoplasmsLiver NeoplasmsNeoplasm Metastasis

Autor:innen und Institutionen

  • Department of Surgery, Duke University Medical Center, Durham, North Carolina.
  • Department of Biostatistics & Bioinformatics, Duke University, Durham, North Carolina.
  • Biostatistics Shared Resource, Duke Cancer Institute, Durham, North Carolina.
  • Duke Cancer Institute, Durham, North Carolina.
  • Department of Surgery, University of Washington, Seattle.
  • Department of Population Health Sciences, Duke University Medical Center, Durham, North Carolina.

Förderung

  • NIAMS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Nierenberg, T. C., Thomas, S. M., Halliday, I., van den Bruele, A. B., Wang, T., Rosenberger, L. H., Flanagan, M. R., DiLalla, G. A., Hwang, E. S., & Plichta, J. K. (2026). Locally Ablative Therapies in Oligometastatic Breast Cancer. JAMA Surgery. https://doi.org/10.1001/jamasurg.2026.0098

Vancouver

Nierenberg TC, Thomas SM, Halliday I, van den Bruele AB, Wang T, Rosenberger LH, et al. Locally Ablative Therapies in Oligometastatic Breast Cancer. JAMA Surgery. 2026. doi:10.1001/jamasurg.2026.0098

BibTeX
@article{Nierenberg2026,
  author = {Nierenberg, Tori C and Thomas, Samantha M and Halliday, Ian and van den Bruele, Astrid Botty and Wang, Ton and Rosenberger, Laura H and Flanagan, Meghan R and DiLalla, Gayle A and Hwang, E Shelley and Plichta, Jennifer K},
  title = {Locally Ablative Therapies in Oligometastatic Breast Cancer},
  journal = {JAMA Surgery},
  year = {2026},
  doi = {10.1001/jamasurg.2026.0098}
}
Kostenlos starten →